We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $55.44 in the latest trading session, marking a -0.14% move from the prior day. This move lagged the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, added 0.61%.
Coming into today, shares of the company had lost 1.26% in the past month. In that same time, the Medical sector lost 0.13%, while the S&P 500 gained 4.86%.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$2.18, up 9.17% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.2 million, up 1901.88% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$6.37 per share and revenue of $221.15 million. These results would represent year-over-year changes of +23.8% and +18359.92%, respectively.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $55.44 in the latest trading session, marking a -0.14% move from the prior day. This move lagged the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, added 0.61%.
Coming into today, shares of the company had lost 1.26% in the past month. In that same time, the Medical sector lost 0.13%, while the S&P 500 gained 4.86%.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$2.18, up 9.17% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.2 million, up 1901.88% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$6.37 per share and revenue of $221.15 million. These results would represent year-over-year changes of +23.8% and +18359.92%, respectively.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.